EXICURE, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.5001 USD | -1.75% |
|
-10.86% | -13.82% |
| 03-22 | North American Morning Briefing : Stocks Struggle After New Records | DJ |
| 02-29 | An unknown buyer agreed to acquire 39.3% stake in Exicure, Inc. from DGP Co.,Ltd. for KRW 6 billion. | CI |
| Sales 2021 | -483K -38.67M | Sales 2022 | 28.83M 2.31B | Capitalization | 5.71M 457M |
|---|---|---|---|---|---|
| Net income 2021 | -64M -5.12B | Net income 2022 | -2M -160M | EV / Sales 2021 | 8.21 x |
| Net cash position 2021 | 24.4M 1.95B | Net cash position 2022 | 1.27M 102M | EV / Sales 2022 | 0.15 x |
| P/E ratio 2021 |
-0.28
x | P/E ratio 2022 |
-2.06
x | Employees | 7 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 54.96% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
More news
| 1 day | -1.75% | ||
| 1 week | -10.86% | ||
| Current month | -16.86% | ||
| 1 month | -19.03% | ||
| 3 months | -5.00% | ||
| 6 months | -21.93% | ||
| Current year | -13.82% |
1 week
0.50
0.57
1 month
0.500.73
Current year
0.500.86
1 year
0.361.50
3 years
0.3660.00
5 years
0.36115.20
10 years
0.36195.00
| Managers | Title | Age | Since |
|---|---|---|---|
Paul Kang
CEO | Chief Executive Officer | 63 | 23/02/23 |
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 30/11/22 |
| Investor Relations Contact | 47 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ji-Young Hwang
DFI | Director of Finance/CFO | 47 | 30/11/22 |
Paul Kang
CEO | Chief Executive Officer | 63 | 23/02/23 |
Hyuk Joon Ko
BRD | Director/Board Member | - | 22/08/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.5001 | -1.75% | 28,416 |
| 25/04/24 | 0.509 | -1.17% | 18,698 |
| 24/04/24 | 0.515 | -4.68% | 18,589 |
| 23/04/24 | 0.5403 | +0.11% | 7,040 |
| 22/04/24 | 0.5397 | -3.80% | 20,107 |
Delayed Quote Nasdaq, April 26, 2024 at 09:00 pm
More quotes
Exicure, Inc. is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The Company is developing nucleic acid therapies targeting ribonucleic acid (RNA) to address both genetic and non-genetic neurological disorders. Its lead program is a non-opioid pain analgesic directed against the genetically validated target SCN9A. It is engaged in discovery efforts across a range of indications and therapeutic targets, such as pain using non-opioid analgesics, as well as rare neurological genetic disorders, including Huntington's disease, Angelman Syndrome, Batten disease, spinocerebellar ataxia, and sporadic amyotrophic lateral sclerosis (ALS). The Company focuses on pursuing out-licensing opportunities for its clinical asset, cavrotolimod, as well as for its preclinical candidates, including the SCN9A program for neuropathic pain.
Calendar
14/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -13.82% | 4.33M | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- XCUR Stock
